This article looks at the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026.
ARK Investment Management LLC, or ARK Invest, is an American investment management firm that oversees several actively managed ETFs. It was founded by Cathie Wood in 2014, who is known for her focus on disruptive technology.
Last month, the firm filed the regulatory 13F form for the fourth quarter of 2025. The submission revealed the portfolio’s value at $15.07 billion, spanning 196 positions, down from $16.80 billion in the prior quarter.
The filings reflect Wood’s appetite for big bets on disruptive innovation, as the figures show an increase in its stake in companies such as Coinbase, CRISPR Therapeutics, Circle Internet Group, Beam Therapeutics, and Tempus AI Inc.
On the other hand, the firm significantly reduced its positions in several big names, like Tesla and Shopify, which experts believe was done to harvest gains from its top holdings.
While talking to CNBC in January, Cathie Wood shared her outlook for 2026. The ARK Invest CEO and CIO said she anticipates strong deflationary pressures this year, with energy, housing, and unit labor prices expected to decline.
With that said, let’s now shift focus to the top picks in Cathie Wood’s stock portfolio for 2026.
Methodology
We scanned the ARK Investment Management portfolio as of December 31, 2025, and ranked the top 10 stocks by the value of ARK’s stake in each company. The figures were sourced from the Insider Monkey Database. Additionally, we also included data on hedge fund holdings in these companies as of Q4 2025 to provide further insight into investor interest.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026
10. Tempus AI, Inc. (NASDAQ:TEM)
Stake Value as of Q4 2025: $446,275,249
Number of Hedge Fund Holders: 41
Tempus AI, Inc. (NASDAQ:TEM) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026. On March 3, the company announced a strategic partnership with Merck to fast-track the development of AI-driven precision medicine and support the pharma-maker’s oncology portfolio and other therapeutic offerings.
As part of the agreement, Merck will leverage Tempus AI, Inc. (NASDAQ:TEM)’s de-identified data and Lens Platform and Workspaces technologies to generate new discoveries and accelerate the development and effective use of candidate therapies on a large scale.
In other news, on February 25, JPMorgan analyst Casey Woodring slashed the stock’s price target to $60 from $80, with a Neutral rating, following the company’s Q4 earnings call a day prior.
According to TipRanks, the firm cited Tempus AI, Inc.’s (NASDAQ:TEM) ‘clouded visibility’ on data upside and a revision to its outlook for Ambry as the reason behind the adjustment.
As of the close of business on March 4, the stock is a Moderate Buy, with an average upside potential of 52.5%.
Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology company that uses artificial intelligence to advance precision medicine.
9. Teradyne, Inc. (NASDAQ:TER)
Stake Value as of Q4 2025: $456,077,004
Number of Hedge Fund Holders: 77
Teradyne, Inc. (NASDAQ:TER) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026, with a stake value of over $456 million, based on the investment management firm’s 13F holdings for the fourth quarter of 2025.
The stock remains on analysts’ radar and currently sports a Moderate Buy rating, with a slight downside potential of 1%, as of the close of business on March 4.
Recent updates include Morgan Stanley analyst Shane Brett on February 12 lifting the firm’s price target on Teradyne, Inc. (NASDAQ:TER) to $306 from $288, while maintaining an Equal Weight rating.
This followed the company’s announcement of strong Q4 2025 results earlier on February 2, with quarterly revenue growing 44% from last year to $1.08 billion and beating estimates of $973.2 million. Non-GAAP EPS stood at $1.80, which came above the high end of its guidance range.
In related news, Teradyne, Inc. (NASDAQ:TER) has forecast revenue and profit for the first quarter of 2026 above Wall Street’s expectations, driven by a surge in investments by tech firms to expand data centers.
Teradyne, Inc. (NASDAQ:TER) designs and develops automated test equipment and advanced robotics systems.
8. Robinhood Markets, Inc. (NASDAQ:HOOD)
Stake Value as of Q4 2025: $543,582,454
Number of Hedge Fund Holders: 83
Robinhood Markets, Inc. (NASDAQ:HOOD) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026. As of the close on March 4, the stock is a consensus Strong Buy, with an average upside potential of 53.2%.
Recent updates include BofA cutting its price target on the stock to $122 from $147 on February 24, while maintaining a Buy rating. The adjustment came as part of the investment bank’s EPS revisions for several brokerage companies, exchanges, and asset managers following their recent earnings calls.
Earlier on February 20, Goldman Sachs analyst James Yaro reduced the price target on Robinhood Markets, Inc. (NASDAQ:HOOD) to $111 from $130. However, the firm maintained a Buy rating on the shares, while noting the company’s strong operating data for January 2026.
In related news, Robinhood Markets, Inc. (NASDAQ:HOOD) reported a record quarterly revenue of $1.28 billion for the fourth quarter. While this was a 27% year-over-year increase, the figure missed analysts’ estimates of $1.34 billion, amid a volatile quarter for digital assets, which adversely impacted crypto trading revenue. However, diluted EPS came in at $0.66, beating estimates by three cents.
Robinhood Markets, Inc. (NASDAQ:HOOD) is a financial services company that provides an electronic trading platform to facilitate the trading of stocks, ETFs, cryptocurrency, and other equities and securities.
7. Advanced Micro Devices, Inc. (NASDAQ:AMD)
Stake Value as of Q4 2025: $551,414,664
Number of Hedge Fund Holders: 132
Advanced Micro Devices, Inc. (NASDAQ:AMD) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026. The stock remains on analysts’ radar and sports a Moderate Buy rating, with an upside potential of 42% as of the close on March 4.
Recent updates include UBS analyst Timothy Arcuri on March 2 reiterating a Buy rating on the stock with a share price target of $310.
This follows Goldman Sachs’ adjustment on February 25, when the firm’s analyst James Schneider lifted the price target to $240 from $210, following the semiconductor company’s recent multi-year strategic partnership with Meta to power its next-gen AI infrastructure through the deployment of 6-gigawatt of AMD GPUs.
The analyst maintained a Neutral rating on the stock. According to a report on TipRanks, industry experts are viewing the deal as an encouraging development for Advanced Micro Devices, Inc. (NASDAQ:AMD)’s share in the accelerator market and a slight setback for Broadcom and Nvidia, considering the fierce competition.
Advanced Micro Devices, Inc. (NASDAQ:AMD) is a global semiconductor company focused on high-performance computing, graphics, and visualization technologies. Its main products include microprocessors, graphics processors, personal computers, workstations, and embedded system applications.
6. CRISPR Therapeutics AG (NASDAQ:CRSP)
Stake Value as of Q4 2025: $551,776,677
Number of Hedge Fund Holders: 32
CRISPR Therapeutics AG (NASDAQ:CRSP) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026, with a stake value of over $551 million as of Q4 2025.
The gene-editing company remains on analysts’ radar and currently carries a Moderate Buy rating, with an average share price upside of 17% as of March 4.
Recent updates include Truist Financial analyst Joon Lee reiterating the firm’s Buy rating on the stock on March 2, according to TipRanks.
Earlier on February 17, Chardan Capital lifted its price target on CRISPR Therapeutics AG (NASDAQ:CRSP) to $76 from $74 and maintained a Buy rating. The adjustment followed the company’s business update and the announcement of its fourth-quarter results on February 12.
According to TipRanks, Chardan analyst Geulah Livshits highlighted the momentum in the company’s siRNA therapies and vivo cardiovascular editing, along with progress across multiple clinical and preclinical programs.
Following the Q4 report, TD Cowen also lifted the price target to $45 from $40 with a Hold rating. The firm noted strong momentum in CASGEVY, with quarterly revenue of $54 million and full-year revenue of $116 million. Moreover, analyst Tyler Van Buren said he was keenly anticipating several clinical updates that are scheduled for the second half of 2026.
CRISPR Therapeutics AG (NASDAQ:CRSP) is a gene editing company focused on developing CRISPR/Cas9-based therapeutics to treat genetically-defined diseases and engineer advanced cellular therapies.
While we acknowledge the potential of TSLA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TSLA and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the ARK Invest Stock Portfolio: Top 5 Stock Picks for 2026.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
Hedge Fund Resource Center